Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anne C. Mailhot
Observed name:
Anne Mailhot
Institutions:
University of Colorado Anschutz,
University of Colorado Denver
Observed institutions:
University of Colorado Anschutz,
University of Colorado Denver
ORCID:
0009-0001-3995-2979
Observed ORCID:
0009-0001-3995-2979
OpenAlex ID:
A5092083762
A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
·
Clinical Cancer Research
·
11
PDF
A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.
2023
·
Breelyn A. Wilky
, Alessandra Maleddu
, et al.
·
Journal of Clinical Oncology
·
10
PDF
Desmoid Tumors—Biology-Driven Management and Treatment Selection
2026
·
Dyda Dao
, Katarzyna Kozak
, et al.
·
American Society of Clinical Oncology Educational Book
·
4
PDF
Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2026
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
·
Clinical Cancer Research
Supplementary Table S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
Supplementary Data S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
Supplementary Table S2 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
PDF
Supplementary Figure S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
Data from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
Supplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
PDF
Supplementary Figure S2 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas
2025
·
Breelyn A. Wilky
, Katherine A. Julian
, et al.
PDF
Show more works
View as search
Works count:
11
Citation count:
25
H-index:
3
I10-index:
2
Year
Topic
Type